<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02850432</url>
  </required_header>
  <id_info>
    <org_study_id>CMRPG3F1311</org_study_id>
    <nct_id>NCT02850432</nct_id>
  </id_info>
  <brief_title>Clinical and MRI Cardiac Biomarkers on Peripheral Arterial Disease in Patients With Long Term DM</brief_title>
  <acronym>CMRPADDM</acronym>
  <official_title>The Evolution and Impact of Clinical and MRI Cardiac Biomarkers on Peripheral Arterial Disease in Patients With Long Term DM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to establish a clinically feasible simultaneous evaluation of heart
      and lower limb using MRI and to assess the combined benefit of clinical and cardiac MRI
      imaging markers in the evaluation of PAD and prediction of treatment outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We expect to enroll about 60 long-term DM patients (&gt;10 years) from main study. Patient will
      receive evaluation of the perfusion in the lower limb by using blood oxygenation-level
      dependent (BOLD) sequence with measurement of the extracellular volume fraction (ECV) as an
      indicator of fibrosis severity in calf muscles. All patients will receive cardiac MRI
      (cardiac function, ischemia and fibrosis) and MR angiography (severity of PAD). The baseline
      studies will be completed within 2 years and 3 additional follow-up studies will be performed
      by the end of 4th year.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2016</start_date>
  <completion_date type="Anticipated">April 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-treatment improvement of peripheral artery disease</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the combined benefit of clinical and MRI imaging parameters (cardiac and lower extremities) in treatment response monitoring and treatment outcome prediction.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Invasive treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endovascular therapy or surgery with medical therapy according to Trans-Atlantic Inter-Society Consensus II scoring system (TASC II)) as described in the main study protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conservative treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rehabilitation with medical therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Invasive treatment</intervention_name>
    <description>Endovascular therapy or surgery with medical therapy according to Trans-Atlantic Inter-Society Consensus II scoring system (TASC II)) as described in the main study protocol</description>
    <arm_group_label>Invasive treatment</arm_group_label>
    <other_name>Surgery or endovascular treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conservative treatment</intervention_name>
    <description>rehabilitation with medical therapy</description>
    <arm_group_label>Conservative treatment</arm_group_label>
    <other_name>rehabilitation with medical therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        The inclusion criteria include:

          1. Able to understand and provide signed informed consent

          2. DM history of 10 years and above

          3. Willing to receive 3 MRI follow-up and serum hematocrit examinations within 2 years,
             if applicable

          4. Willing to receive standard therapy such as surgery or medication

          5. Age between 18-80 years old

        The exclusion criteria include:

          1. Pregnant or breast-feeding women

          2. Allergic MRI contrast medium

          3. Absolute contraindications to contrast MRI (e.g., metallic hazards, hemodynamic
             instability, pregnancy, known allergy to contrast medium).

          4. Contraindicated to MRI study: cardiac pacemaker, cochlear implantation, metallic
             object within eyeball

          5. Patients that refuse to, or has poor ability of understanding and comply study
             conditions, such as severe dementia or difficulty in mobility

          6. Patients having dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu-Hsiang Juan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yu-Hsiang Juan, MD</last_name>
    <phone>+886-9-753-66388</phone>
    <email>Jonat126@yahoo.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Gueishan</city>
        <state>Taoyuan</state>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu-Hsiang Juan, MD</last_name>
      <phone>+886-9-75366388</phone>
      <email>Jonat126@yahoo.com.tw</email>
    </contact>
    <investigator>
      <last_name>Yu-Hsiang Juan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu-Ching Lin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chun-Chin Chang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chen-Ming Sung</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jiun-jie Wang, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gigin Lin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yun-Chung Cheung, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shu-Hang Ng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Koon-Kwan Ng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jim Wu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu-Chun Lin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2016</study_first_submitted>
  <study_first_submitted_qc>July 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2016</study_first_posted>
  <last_update_submitted>April 6, 2017</last_update_submitted>
  <last_update_submitted_qc>April 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Yu-Hsiang Juan</investigator_full_name>
    <investigator_title>Primary investigator</investigator_title>
  </responsible_party>
  <keyword>Magnetic resonance imaging</keyword>
  <keyword>Extracellular volume matrix fraction</keyword>
  <keyword>Peripheral artery disease</keyword>
  <keyword>Blood-oxygen level dependent</keyword>
  <keyword>Cardiac function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>We have to see if this corresponds to the IRB regulation.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

